T. Rowe Price boosts Apogee Therapeutics holding to 772,969 shares (NASDAQ: APGE)

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. reports beneficial ownership of 772,969 shares of Apogee Therapeutics common stock, representing 1.3% of the class as of 06/30/2026. The filing is an Amendment No. 2 to a Schedule 13G/A and affirms ownership of 5% or less.

The filing states sole voting power for 751,471 shares and sole dispositive power for 772,969 shares. The reporting person denies beneficial ownership in a declaratory statement. The filing is signed by Ellen York, Vice President, on 07/08/2026.

Insights

Institutional Ownership Analyst

T. Rowe Price holds a 1.3% passive stake in Apogee Therapeutics as reported on a Schedule 13G/A.

The filing shows a passive reporting posture under Schedule 13G/A with 772,969 shares and sole voting power over 751,471 shares as of 06/30/2026. The declaratory statement denying beneficial ownership is typical language when an investment manager reports on behalf of clients.

Cash‑flow treatment and intent are not described in the excerpt; subsequent filings or disclosures would show any change in status from passive to active ownership.

Compliance & Reporting Specialist

The amendment updates a Schedule 13G/A position and includes claim language disclaiming beneficial ownership.

The form lists precise voting and dispositive counts and attaches a signature dated 07/08/2026. The filing uses standard Schedule 13G/A mechanics for institutional investors owning under 5%.

Regulatory impact is routine; monitor future amendments only if the reported percentage crosses the 5% threshold or the filing converts to a Schedule 13D.

Key Figures

Beneficially owned: 772,969 shares Percent of class: 1.3% Sole voting power: 751,471 shares +2 more

5 metrics

Beneficially owned 772,969 shares as of 06/30/2026

Percent of class 1.3% ownership percentage as reported

Sole voting power 751,471 shares voting power count in filing

Form type Schedule 13G/A Amendment No. 2 reporting vehicle for institutional passive holdings

Signature date 07/08/2026 filing signed by Ellen York, Vice President

Key Terms

Schedule 13G/A, Beneficial ownership, Sole dispositive power, CUSIP

4 terms

Schedule 13G/A regulatory

"Amendment No. 2 to a Schedule 13G/A for reporting passive institutional holdings"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficial ownership financial

"Amount beneficially owned: 772969 and Percent of class: 1.3%"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 772969"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

CUSIP technical

"CUSIP No.: 03770N101"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/08/2026 - 11:30 AM Accepted by SEC EDGAR 07/08/2026 - 11:30 AM Learn about SEC filing dates

FAQ

What stake does T. Rowe Price report in Apogee Therapeutics (APGE)?

T. Rowe Price reports beneficial ownership of 772,969 shares, representing 1.3% of Apogee Therapeutics common stock as of 06/30/2026. The filing is an Amendment No. 2 to a Schedule 13G/A signed on 07/08/2026.

Does the Schedule 13G/A show voting or disposition powers for APGE shares?

Yes. The filing states sole voting power for 751,471 shares and sole dispositive power for 772,969 shares. Shared voting and dispositive powers are reported as 0 in the excerpt.

Is T. Rowe Price claiming beneficial ownership of the APGE shares?

The filing includes a declaratory statement denying beneficial ownership, a common clause for investment managers reporting on behalf of clients. The form still lists voting and dispositive powers tied to 772,969 shares as of 06/30/2026.

Does this Schedule 13G/A trigger any 5% ownership disclosure thresholds?

No. The reported stake is 1.3%, below the 5% reporting threshold. The form is consistent with institutional passive reporting requirements under Schedule 13G/A for holdings under 5%.

What dates are relevant in this filing for APGE ownership?

The reported ownership is tied to 06/30/2026 and the amendment is signed on 07/08/2026. These dates appear in the filing and identify the position measurement and signature date.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

APOGEE THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

03770N101

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 03770N101

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 751,471.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 772,969.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

772,969.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.3 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: APOGEE THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM, MA, 02453
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 03770N101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 772969
(b)	Percent of class: 1.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 751471
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 772969
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	07/08/2026